To include your compound in the COVID-19 Resource Center, submit it here.

Obatoclax: Phase II data

An open-label, international Phase II trial in 155 patients showed that IV obatoclax plus carboplatin and etoposide missed the primary endpoint of significantly improving ORR vs. carboplatin and etoposide (64.9% vs. 53.8%,

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE